Tags : SARS-CoV-2

ViewPoints Interview: Maxwell Biosciences’ Dr. Gill Diamond and Joshua McClure

Tuba Khan June 7, 2021

In an interview with PharmaShots, Dr. Gill Diamond, Scientific Advisory Board Member and Joshua McClure, CEO and Co-founder of Maxwell Biosciences share their views on the news findings of the company published in MDI that demonstrated that several peptoids exhibit potent in vitro antiviral activity against both HSV-1 and SARS-CoV-2. Shots: The studies showed that […]Read More

Viewpoints

ViewPoints Article: Recent Insights into Advances of COVID-19 Treatment

Dr. Anish Desai (Guest Author) May 27, 2021

Introduction: The current century has witnessed the universal spread of the unknown species of coronaviruses. The rapid deterioration of the public health system with changes in ecology and urbanization has accelerated more recurrent epidemics, which become more troublesome to prevent and contain promptly. A novel coronavirus (CoV) emerged in December 2019, is associated with respiratory […]Read More

Biotech

BMS and Xencor Collaborate to Use Xtend XmAb Technology in

Tuba Khan May 26, 2021

Shots: BMS to get non-exclusive access to Xencor’s Xtend Fc technology to extend the half-life of a novel Ab combination therapy that is intended to neutralize the SARS-CoV-2 virus to prevent COVID-19 BMS will solely lead research, development, regulatory and commercial activities for SARS-CoV-2 mAb Duo. Xencor is eligible to receive royalties from the sales […]Read More

MedTech

Qiagen’s PCR Tests Demonstrate Effectiveness in Detecting Mutations in SARS-CoV-2

Tuba Khan January 21, 2021

Shots: Qiagen’s QIAstat-Dx and NeuMoDx tests remain accurate & effective in detecting SARS-CoV-2 infections The company started cross-checking variants in May’2020 & assessed the tests against genetic mutations of the virus uploaded to the GISAID and GenBank public databases. Qiagen will continue to conduct assessments on a biweekly basis Variants with potentially increased transmissibility include […]Read More

Clinical Trials

Sorrento Presents Preliminary Results of STI-2020 Against COVID-19

Tuba Khan January 20, 2021

Shots: The company presents the ongoing program of SARS-CoV-2 mutation surveillance for STI-2020 currently in pre/ clinical development for COVID-19 The data provides evidence of maintained binding potency in in vitro assays including the Spike amino acid changes found in SARS-CoV-2 viruses of the B.1.1.7 lineage, identified in the UK Additional neutralizing Abs were identified […]Read More

Viewpoints

ViewPoints Interview: Neoleukin’s Daniel-Adriano Silva Shares Insight on Novel Protein

Tuba Khan December 22, 2020

In a recent interview with PharmaShots Daniel-Adriano Silva, PhD, Co-founder and Vice President Head of Research at Neoleukin shared the significance and promise of the findings published in Science and discuss the details of its De Novo Protein Design Shots: NL-CVX1 (CTC-445.2d) demonstrated the ability to prevent infection of multiple human cell lines in vitro and […]Read More

COVID-19 MedTech

Roche Launches Elecsys SARS-CoV-2 Antigen Test to Support High-Volume COVID-19

Tuba Khan December 11, 2020

Shots: Roche has launched Elecsys SARS-CoV-2 Ag test as an aid in the diagnosis of SARS-CoV-2 infections, in the markets accepting the CE Mark. Additionally, Roche has also filed a EUA to the US FDA The test showed 94.5% sensitivity across 200 PCR confirmed symptomatic individuals & 99.9% specificity across 2747 PCR negative symptomatic & […]Read More

MedTech

Qiagen Launches Portable Digital SARS-CoV-2 Antigen Test in the US

Tuba Khan November 13, 2020

Shots: Qiagen has initiated the commercialization of the portable digital QIAreach SARS-CoV-2 antigen test in the US that can be used by laboratories to detect active infections in 2-15mins. The test provides a higher throughput testing for SARS-CoV-2 antigen by processing up to 8 tests/ hub. The digital results do not need subjective interpretation and […]Read More

MedTech

Roche to Launch Elecsys SARS-CoV-2 Antigen Test for Suspected COVID-19

Tuba Khan October 13, 2020

Shots: Roche plans to launch a high-volume SARS-CoV-2 Antigen test to aid the diagnosis of SARS-CoV-2 infection. Roche intends to file US FDA’s EUA while the test is expected to be available at the end of 2020 for markets accepting the CE Mark The test will run on all Roche cobas e immunochemistry analyzers and […]Read More

Regulatory

BioNTech and Pfizer Initiates Rolling Submission to EMA for SARS-CoV-2

Vartika Singh October 7, 2020

Shots: The Rolling Submission is based on the preliminary results from pre-clinical and early clinical studies in adults, which shows that BNT162b2 triggers the production of neutralizing antibodies and TH-1 dominant CD4+ and CD8+ T cells that target SARS-CoV-2. BioNTech and Pfizer plan to work with the EMA’s CHMP to complete the rolling review process […]Read More

Takeda Enters into an Exclusive License Agreement with Mirum to Develop and Commercialize Maralixibat for Rare Pediatric Liver Diseases in Japan

Amgen Collaborates with Verastem to Evaluate VS-6766 + Lumakras (Sotorasib) in P-I/II Trial for KRAS G12C-Mutant Non-Small Cell Lung Cancer

Immunic Sign a License Agreement with University Medical Center Goettingen for IMU-838 & N4-Hydroxycytidine to Treat Viral Infections

AbCellera Enters into a License Agreement with Everest to Discover Antibody Therapies

Samsung Bioepis and Biogen’s Byooviz (biosimilar, ranibizumab) Receives the US FDA’s Approval for the Treatment of Retinal Vascular Disorders

Samsung Bioepis Reports Results of Post-Hoc Analysis from P-III Study of Byooviz (biosimilar, ranibizumab) for the Treatment of nAMD

Immunic Sign a License Agreement with University Medical Center Goettingen for IMU-838 & N4-Hydroxycytidine to Treat Viral Infections

Gilead Reports Results of Veklury (remdesivir) in P-III Trial for the Treatment of COVID-19

Incyte’s Jakafi (ruxolitinib) Receives the US FDA’s Approval for the Treatment of Chronic Graft-Versus-Host Disease

Innovent Reports NMPA’s Acceptance of sNDA for Sintilimab as 1L Treatment for Esophageal Squamous Cell Carcinoma

Gilead Reports Results of Veklury (remdesivir) in P-III Trial for the Treatment of COVID-19

Vigeo Reports Completion of VT1021 in P-I/II Study for the Treatment of Recurrent Glioblastoma and Pancreatic Cancer

Tags : SARS-CoV-2

ViewPoints Interview: Maxwell Biosciences’ Dr. Gill Diamond and Joshua McClure

ViewPoints Article: Recent Insights into Advances of COVID-19 Treatment

BMS and Xencor Collaborate to Use Xtend XmAb Technology in

Qiagen’s PCR Tests Demonstrate Effectiveness in Detecting Mutations in SARS-CoV-2

Sorrento Presents Preliminary Results of STI-2020 Against COVID-19

ViewPoints Interview: Neoleukin’s Daniel-Adriano Silva Shares Insight on Novel Protein

Roche Launches Elecsys SARS-CoV-2 Antigen Test to Support High-Volume COVID-19

Qiagen Launches Portable Digital SARS-CoV-2 Antigen Test in the US

Roche to Launch Elecsys SARS-CoV-2 Antigen Test for Suspected COVID-19

BioNTech and Pfizer Initiates Rolling Submission to EMA for SARS-CoV-2

Latest Posts

ViewPoints Article: 5 Technologies That Redefines Human Medicine and Therapeutics

Immunic Sign a License Agreement with University Medical Center Goettingen for IMU-838 & N4-Hydroxycytidine to Treat Viral Infections

Gilead Reports Results of Veklury (remdesivir) in P-III Trial for the Treatment of COVID-19

Incyte’s Jakafi (ruxolitinib) Receives the US FDA’s Approval for the Treatment of Chronic Graft-Versus-Host Disease

Tags : SARS-CoV-2

Latest Posts

Categories

Related Topics